Evaluation of Chagas Blood Screening and Confirmatory Assays

Evaluation of ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay

Protocol designed to test blood samples from blood donors of whole blood and blood components using a new investigational screening test (PRISM Chagas) that detects antibody to T. cruzi (Chagas infection). Results will be compared to the current T. cruzi antibody screening assay. Specimens positive with the screening assay will be further tested with a new investigational Chagas confirmatory assay [Enzyme Strip Assay (ESA) Chagas]. Additional specimens collected under separate protocols or sourced from suppliers will also be provided to the clinical sites for testing with PRISM Chagas assay and ESA Chagas.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay; Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay

• Study Type: Interventional
• Enrollment (Actual): 41862
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Lakeland, Florida, United States, 33805
      • BloodNet USA
    • St. Petersburg, Florida, United States, 33716
      • Florida Blood Services
  • Illinois
    • Glenview, Illinois, United States, 60025
      • LifeSource Blood Center
  • North Carolina
    • Charlotte, North Carolina, United States, 28273
      • American Red Cross Charlotte NTL
  • Oregon
    • Portland, Oregon, United States, 97220
      • American Red Cross
  • Rhode Island
    • Providence, Rhode Island, United States, 02908
      • Rhode Island Blood Center
  • Texas
    • San Antonio, Texas, United States, 78201
      • South Texas Blood and Tissue Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy donors that have consented to participate in study

Exclusion Criteria:

• N/A

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; All subjects will have their blood tested by the investigational Chagas screening assay.	Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay; Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.; Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay; Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
Experimental: 2; Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.	Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay; Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.; Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay; Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PRISM Chagas Specificity	Total of 16,249 serum and plasma blood donor specimens tested with PRISM Chagas assay during design validation phase. Repeatedly reactive specimens were tested further with a supplemental assay [radioimmune precipitation assay (RIPA)].	6 months
PRISM Chagas Sensitivity	Specimens from subjects known to be T cruzi parasite positive were tested with PRISM Chagas assay.	6 months
ESA Chagas Specificity	Preselected US blood donor specimens (330) presumed T cruzi antibody negative negative that were tested only with the investigational ESA Chagas.	3 months
ESA Chagas Sensitivity	Specimens from individuals known to be T cruzi parasite positive were tested with ESA Chagas assay.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PRISM Chagas Reactivity Serology Positive Specimens	Total of 85 specimens from subjects from South America known to be positive for T cruzi antibodies and 202 US blood donor specimens that were repeatedly reactive on a licensed test for antibodies to T cruzi were tested with the PRISM Chagas assay and supplemental testing (RIPA).	4 months
PRISM Chagas Reactivity in Chagas Endemic Population	Population of specimen collected in Chagas endemic area in South/Central America (524) were tested to demonstrate reactivity with the PRISM Chagas assay in a population with a 5% or greater prevalence of infection with T cruzi antibody. specimens tested with PRISM Chagas assay and licensed test for T cruzi antibody and if repeatedly reactive with either assay the specimens were tested with supplemental assay (RIPA). Data presented with PRISM Chagas and RIPA results.	2 months
ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas.	A total of 41,760 US blood donor specimens were tested by ABBOTT PRISM Chagas. Of these specimens, 58 out of 79 specimens were T cruzi antibody repeatedly reactive by ABBOTT PRISM Chagas (26 from 16,249 donor specimens tested in design validation phase and 32 from 25,511 specimens from the Chagas extended evaluation). Donor specimens that were repeatedly reactive with the licensed T cruzi antibody assay, but PRISM Chagas nonreactive (6) and specimens PRISM Chagas grayzone negative (15) were excluded from this analysis.	15 months
ESA Chagas Sensitivity in Serologically Positive Non-US Specimens	ESA Chagas Sensitivity in a non-US population was determined for the 85 out of the total 287 serologically positive specimens (202 US Serology Positive specimens were excluded). These specimens were collected from individuals positive for T cruzi antibodies based on 2 different serologic tests for antibodies to T cruzi in Argentina and were tested with ESA Chagas.	3 months
ESA Chagas Testing in Chagas Endemic Population	Specimen collected in Chagas endemic areas in South or Central America (524) tested with ESA Chagas and licensed test for T cruzi antibody. Specimens repeatedly reactive with either screening assay and/or ESA Chagas positive were tested with supplemental assay (RIPA). Presentation of ESA Chagas results for 132 specimens from a Chagas endemic population that were RIPA positive.	2 months

Collaborators and Investigators

• Sponsor: Abbott Diagnostics Division
• Investigators: Principal Investigator: Susan Stramer, PhD, American National Red Cross; Principal Investigator: Sharon Gordon, LifeSource; Principal Investigator: Norman Kalmin, MD, South Texas Blood and Tissue Center; Principal Investigator: Carolyn T Young, MD, Rhode Island Blood Center; Principal Investigator: Deborah Williams, Florida Blood Services; Principal Investigator: Pauline Simmonds-Brown, Blood Net USA

Study record dates

Study Major Dates

• Study Start: June 1, 2008
• Primary Completion (Actual): July 1, 2009
• Study Completion (Actual): September 1, 2009

Study Registration Dates

• First Submitted: July 16, 2008
• First Submitted That Met QC Criteria: July 16, 2008
• First Posted (Estimate): July 18, 2008

Study Record Updates

• Last Update Posted (Estimate): March 7, 2012
• Last Update Submitted That Met QC Criteria: March 2, 2012
• Last Verified: February 1, 2012

More Information

Terms related to this study

• Keywords: healthy donors
• Other Study ID Numbers: 7B5-02-06P06